Lyell Immunopharma

Lynn Seely, M.D. has served as a member of the board of directors since April 2016. Currently, Dr. Seely serves as president and chief executive officer of Lyell Immunopharma, a clinical-stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors. Previously, Dr. Seely was president, chief executive officer and a member of the board of directors of Myovant Sciences, Inc. a biopharmaceutical company focused on developing and commercializing innovative therapies for women’s and men’s health. Prior to joining Myovant, Dr. Seely served as the chief medical officer of Medivation, Inc, where she led development of XTANDI (enzalutamide) from the first-in-human clinical trial through global approvals. Dr. Seely has held clinical development roles at Anesiva, Inc. (formerly Corgentech Inc.), Cytyc Health Corporation, ProDuct Health, and Chiron Corporation. Dr. Seely received an M.D. from the University of Oklahoma College of Medicine, completed her residency and served as chief resident in internal medicine at Yale-New Haven Hospital, and did a fellowship in endocrinology and metabolism at the University of California, San Diego.